EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC 4.0

Predictors and mortality risk of venous thromboembolism in patients with COVID-19: systematic review and meta-analysis of observational studies

Gaurav Agarwal, Adrija Hajra iD, Sandipan Chakraborty, Neelkumar Patel, Suman Biswas, Mark K Adler, Carl J Lavie

Therapeutic Advances in Cardiovascular Disease · 2022-01 · 16

DOI: 10.1177/17539447221105013 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Therapeutic Advances in Cardiovascular Disease, online erschienen am 28.06.2022. Verfasst von Gaurav Agarwal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jersey City Medical Center, Jersey City, NJ, USA. Hauptthemen laut MEDLINE: COVID-19, Venous Thromboembolism. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection resulting in COVID-19 disease is associated with widespread inflammation and a prothrombotic state, resulting in frequent venous thromboembolic (VTE) events. It is currently unknown whether anticoagulation is protective for VTE events. Therefore, we conducted a systematic review to identify predictors of VTE in COVID-19.

Methods

We searched PubMed, EMBASE, Google Scholar, and Ovid databases for relevant observational studies of VTE in COVID-19 disease. The effect size for predictors of VTE was calculated using a random-effects model and presented as forest plots. Heterogeneity among studies was expressed as Q statistics and I 2 . Bias was assessed using the Newcastle Ottawa Scale for all identified observational studies. Publication bias was assessed with funnel plot analysis.

Results

We identified 28 studies involving 6053 patients with suspected or confirmed COVID-19. The overall pooled prevalence of VTE events was 20.7%. Male sex was associated with a higher risk of VTE events, whereas prior history of VTE, smoking, and cancer were not. VTE events were significantly higher in severely ill patients, mechanically ventilated patients, those requiring intensive care admission, and those with a low PaO 2 /FiO 2 ratio (P/F ratio). Chronic comorbidities, including cardiovascular disease, heart failure, renal disease, and pulmonary disease, did not increase the risk of VTE events. Patients with VTE had higher leukocyte counts and higher levels of D-dimer, C-reactive protein, and procalcitonin. The occurrence of VTE was associated with increased length of stay but did not impact mortality. Therapeutic and prophylactic doses of anticoagulation were not protective against VTE.

Conclusion

VTE in COVID-19 is associated with male gender and severe disease but not with traditional risk factors for VTE. The occurrence of VTE does not appear to be mitigated by either prophylactic or therapeutic anticoagulation. The occurrence of VTE in this population is associated with an increased length of stay but does not appear to impact mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Venous ThromboembolismAnticoagulantsBlood CoagulationHumansMaleSARS-CoV-2

Stichwörter der Autor:innen

COVID-19anticoagulationmortality riskthromboembolismthrombosis

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Jersey City Medical Center, Jersey City, NJ, USA.
  • Jacobi Medical Center and Albert Einstein College of Medicine, Bronx, 2562 Laconia Avenue, Bronx, NY 10469, USA.
  • Miami Valley Hospital, Columbus, OH, USA.
  • The University of Kansas, Kansas City, KS, USA.
  • Rochester Regional Health, Rochester, NY, USA.
  • Interfaith Medical Center, Brooklyn, NY, USA.

ORCID-Profile: Adrija Hajra

Zitieren

APA

Agarwal, G., Hajra, A., Chakraborty, S., Patel, N., Biswas, S., Adler, M. K., & Lavie, C. J. (2022). Predictors and mortality risk of venous thromboembolism in patients with COVID-19: systematic review and meta-analysis of observational studies. Therapeutic Advances in Cardiovascular Disease, 16. https://doi.org/10.1177/17539447221105013

Vancouver

Agarwal G, Hajra A, Chakraborty S, Patel N, Biswas S, Adler MK, et al. Predictors and mortality risk of venous thromboembolism in patients with COVID-19: systematic review and meta-analysis of observational studies. Therapeutic Advances in Cardiovascular Disease. 2022;16. doi:10.1177/17539447221105013

BibTeX
@article{Agarwal2022,
  author = {Agarwal, Gaurav and Hajra, Adrija and Chakraborty, Sandipan and Patel, Neelkumar and Biswas, Suman and Adler, Mark K and Lavie, Carl J},
  title = {Predictors and mortality risk of venous thromboembolism in patients with COVID-19: systematic review and meta-analysis of observational studies},
  journal = {Therapeutic Advances in Cardiovascular Disease},
  year = {2022},
  volume = {16},
  doi = {10.1177/17539447221105013}
}
Kostenlos starten →